ProCE Banner Activity

Pooled Analysis of Phase I/II and Phase III Trials of Lovotibeglogene Autotemcel Gene Therapy in Patients With Sickle Cell Disease

Conference Coverage

In this pooled analysis of the HGB-206 and HGB-210 trials, lovo-cel was associated with complete resolution of vaso-occlusive events and serious vaso-occlusive events in nearly all patients with sickle cell disease.

Released: December 13, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.